REDEMPLO® (plozasiran) is a prescription medicine from Arrowhead Pharmaceuticals for adults with familial chylomicronemia syndrome (FCS). Used alongside a low-fat diet, the 25 mg injection is intended to reduce triglycerides, a type of fat in the blood. The brand’s patient website explains how the treatment works, shares clinical results, and provides information about dosing, access and support, and patient experiences.

REDEMPLO is administered as one dose every three months. In the clinical study described on the site, patients taking REDEMPLO had an 80% median reduction in triglycerides from baseline at Month 10, compared with a 17% reduction for placebo. The study also recorded fewer patients with acute pancreatitis attacks in the REDEMPLO group than in the placebo group; the medicine has not been proven to reduce such attacks.

The site offers patient information, instructions for use, safety details, and updates about the Rely On REDEMPLO Patient Support Program. Common side effects include increased blood sugar, headache, nausea, and injection-site reactions.